Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
FK506-binding protein 1A (FKBP12), also known as macrophilin‑12 or tacrolimus binding protein 1A, is a small intracellular immunophilin with peptidyl-prolyl cis-trans isomerase activity. It binds with high affinity to immunosuppressive drugs such as tacrolimus and pimecrolimus. Upon drug binding, the resulting complex inhibits the phosphatase calcineurin in T cells, thereby suppressing immune responses by blocking cytokine production. Beyond its role in immunity, FKBP12 modulates calcium release channels and participates in various cellular processes including signal transduction and protein folding.
Drugs such as pimecrolimus and tacrolimus bind to macrophilin‑12/FKBP12, forming a complex that inhibits the phosphatase calcineurin. This blocks T-cell activation by preventing dephosphorylation of NFAT transcription factors and subsequent cytokine gene expression.
1 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on FK506-binding protein 1A (FKBP12).